Stocks Health care HURA
NASDAQ · Health careTuHURA Biosciences, Inc. (HURA)
It posted a net loss of $30.6M. In fiscal 2025 capital spending exceeded operating cash flow by $27.7M. At June 30, 2026 it held $996K in cash against $3.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 14, 2026.
Key facts about TuHURA Biosciences, Inc.
- Net worth
- TuHURA Biosciences, Inc. has a market value (market cap) of $105.8M at the latest share price, and shareholders' equity of $18.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $0, with a net loss of $30.1M.
- Cash flow
- In fiscal 2025 operations used $27.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 14, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- TuHURA Biosciences, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What TuHURA Biosciences, Inc. does
TuHURA Biosciences, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker HURA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $0 | -$30.1M | -$0.63 | -$27.7M |
| 2024 | $0 | -$21.7M | -$1.21 | -$14.8M |
| 2024 | n/a | -$8.3M | -$0.32 | n/a |
| 2024 | $0 | -$29.3M | -$2.47 | -$12M |
| 2023 | n/a | -$14.6M | -$9.27 | n/a |
| 2022 | n/a | -$22.7M | -$25.80 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What TuHURA Biosciences, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 6, 2026New debt 8-K
- October 16, 2026New debt 8-K
- September 24, 2026New debt 8-K
- September 17, 2026New debt 8-K
- September 17, 2026
- September 16, 2026
- September 4, 2026New debt 8-K
- August 28, 2026Activist stake changed SCHEDULE 13D/A
- August 21, 2026New debt 8-K
- August 19, 2026
Insider trades
What the people running TuHURA Biosciences, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| May 28, 2026 | Bianco James A.Chief Executive Officer, Director | Gave as a gift | 150,000 | - |
Who owns HURA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Highbridge Capital Management, LLC13G, passive | 9.1% | February 17, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 90 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Vanguard Capital Management LLC | 2,267,901 | +193,673 |
| Northern Trust Corp | 1,621,042 | +1,322,855 |
| BlackRock, Inc. | 690,088 | -1,760,168 |
| Geode Capital Management, LLC | 484,219 | -502,703 |
| Millennium Management LLC | 454,535 | new |
| Aqr Capital Management LLC | 424,600 | -182,568 |
| Vanguard Fiduciary Trust Co | 251,186 | -35,947 |
| Citadel Advisors LLC | 232,319 | new |
| State Street Corp | 188,404 | -324,509 |
| Jane Street Group, LLC | 163,891 | new |
| Apollon Wealth Management, LLC | 156,519 | -1,491 |
| Qube Research & Technologies Ltd | 145,595 | new |
| Morgan Stanley | 143,257 | +119,424 |
| Goldman Sachs Group Inc | 131,768 | +61,522 |
| Bank of New York Mellon Corp | 121,662 | -89,906 |
| XTX Topco Ltd | 100,424 | +88,911 |
| WealthShield Partners, LLC | 91,530 | 0 |
| Aster Capital Management (DIFC) Ltd | 89,690 | new |
| Captrust Financial Advisors | 88,373 | new |
| Cetera Investment Advisers | 61,620 | -78,624 |
Insiders
1 insiders reported holding 2,173,307 shares in total, about $3.6M at the last price.
| Holder | Shares |
|---|---|
| Bianco James A.Chief Executive Officer, Director | 2,173,307 |
Questions about HURA
What does TuHURA Biosciences, Inc. do?
TuHURA Biosciences, Inc. is a company in the Health care sector, listed on NASDAQ as HURA. Its shares trade on NASDAQ under the ticker HURA.
What is TuHURA Biosciences, Inc.'s net worth?
TuHURA Biosciences, Inc. has a market value (market cap) of $105.8M at the latest share price, and shareholders' equity of $18.5M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is TuHURA Biosciences, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $30.6M.
When did TuHURA Biosciences, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 14, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the new debt from November 6, 2026.
When is TuHURA Biosciences, Inc.'s next earnings report?
TuHURA Biosciences, Inc.'s next report is expected around November 13, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare HURA with
Follow HURA
Get an email when TuHURA Biosciences, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values TuHURA Biosciences, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.